AR068553A1 - Vacunas y componentes de vacuna para la inhibicion de celulas microbianas - Google Patents

Vacunas y componentes de vacuna para la inhibicion de celulas microbianas

Info

Publication number
AR068553A1
AR068553A1 ARP080104173A ARP080104173A AR068553A1 AR 068553 A1 AR068553 A1 AR 068553A1 AR P080104173 A ARP080104173 A AR P080104173A AR P080104173 A ARP080104173 A AR P080104173A AR 068553 A1 AR068553 A1 AR 068553A1
Authority
AR
Argentina
Prior art keywords
peptides
microbial cells
polypeptides
vaccines
inhibition
Prior art date
Application number
ARP080104173A
Other languages
English (en)
Original Assignee
Pastoral Greenhouse Gas Res Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pastoral Greenhouse Gas Res Lt filed Critical Pastoral Greenhouse Gas Res Lt
Publication of AR068553A1 publication Critical patent/AR068553A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
    • Y02P60/22—Methane [CH4], e.g. from rice paddies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Componentes de células microbianas que son utiles para produccion de anticuerpos, incluyendo péptidos, polipéptidos que comprenden estos péptidos, polinucleotidos que codifican estos péptidos o polipéptidos, y anticuerpos dirigidos a estos péptidos, polipéptidos o polinucleotidos. También se incluye vectores de expresion y células huésped para producir los métodos y composiciones, especialmente composiciones de vacunas, para detectar, dirigir e inhibir células microbianas, especialmente células metanogenas, usando uno o más de los péptidos, polipéptidos, polinucleotidos, anticuerpos, vectores de expresion y células huésped revelados.
ARP080104173A 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas AR068553A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97510407P 2007-09-25 2007-09-25
US98984007P 2007-11-22 2007-11-22
US98984107P 2007-11-22 2007-11-22

Publications (1)

Publication Number Publication Date
AR068553A1 true AR068553A1 (es) 2009-11-18

Family

ID=40511642

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
ARP080104172A AR068552A1 (es) 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP080104172A AR068552A1 (es) 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas

Country Status (17)

Country Link
US (7) US8586709B2 (es)
EP (5) EP2203470A4 (es)
JP (5) JP5552053B2 (es)
CN (4) CN101918431B (es)
AR (3) AR068553A1 (es)
AU (4) AU2008304019A1 (es)
BR (5) BR122020023381B1 (es)
CA (3) CA2700162C (es)
CL (3) CL2008002860A1 (es)
DK (3) DK2203466T3 (es)
ES (3) ES2895908T3 (es)
MX (3) MX340736B (es)
NZ (1) NZ745324A (es)
RU (1) RU2528854C2 (es)
UY (3) UY31359A1 (es)
WO (3) WO2009041830A2 (es)
ZA (1) ZA201001933B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340736B (es) * 2007-09-25 2016-07-22 Pastoral Greenhouse Gas Res Ltd * Vacunas y componentes de vacunas para inhibicion de celulas microbianas.
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
BRPI1015203B1 (pt) * 2009-06-26 2021-06-01 Lysando Ag Proteína de fusão composta por uma endolisina e uma extensão de peptídeo anfifática, usos da mesma e composição farmacêutica que compreende a dita proteína
KR20170024129A (ko) * 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 항균제
AR077992A1 (es) * 2009-08-27 2011-10-05 Pastoral Greenhouse Gas Res Ltd Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium
CN103119158B (zh) * 2010-04-27 2015-04-08 莱桑多公司 减少生物膜的方法
CN104837859B (zh) * 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
CN110540991B (zh) 2013-03-15 2023-10-24 通用医疗公司 使用截短的引导RNA(tru-gRNA)提高RNA引导的基因组编辑的特异性
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
EA038321B1 (ru) * 2014-11-06 2021-08-09 Е.И. Дюпон Де Немур Энд Компани Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки
CN104789675A (zh) * 2015-04-15 2015-07-22 江苏师范大学 一种检测荷斯坦奶牛瘤胃微生物的方法
US11845928B2 (en) * 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
BR112018077483A2 (pt) * 2016-07-14 2019-04-02 Basf Se meio de fermentação, métodos para cultivar um microrganismo e para produzir um composto de interesse, solução de oligoelemento para um processo de fermentação, e, uso de um agente quelante.
CA3048863A1 (en) * 2016-12-29 2018-07-05 Illumina, Inc. Analysis system for orthogonal access to and tagging of biomolecules in cellular compartments
WO2018126499A1 (zh) * 2017-01-05 2018-07-12 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
US10745439B2 (en) * 2017-03-20 2020-08-18 Regents Of The University Of Minnesota Kinase substrates and methods of use thereof
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
KR102647714B1 (ko) * 2018-03-19 2024-03-18 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
WO2020102591A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
CN109627301B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin固体稳定剂开发及应用
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
EP4037666B1 (en) 2020-12-08 2024-05-01 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113121705B (zh) * 2021-04-19 2023-03-24 成都英普博集生物科技有限公司 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用
US20240009291A1 (en) * 2022-07-11 2024-01-11 Arkea Bio Corp. Compositions and methods for reducing methane emissions in ruminant populations
WO2024097397A1 (en) * 2022-11-03 2024-05-10 Helix Nanotechnologies, Inc. Ruminal and methanogen vaccines and uses thereof
CN115938486B (zh) * 2022-12-06 2023-11-10 内蒙古农业大学 基于图神经网络的抗菌性乳酸菌株筛选方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159861A (en) * 1875-02-16 Improvement in brooms
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IT1180166B (it) * 1983-05-03 1987-09-23 Ssm Int Chem Co Ltd Composizione ad attivita' farmaceutica perfezionata e sua utilizzazione per usi veterinari
GB8815968D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Veterinary devices
JPH05219927A (ja) * 1992-02-14 1993-08-31 Gumma Pref Gov 飼料の混合装置及び混合飼料の製造方法
JP3651915B2 (ja) * 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
ES2218530T3 (es) 1993-10-19 2004-11-16 Commonwealth Scientific And Industrial Research Organisation Uso de una preparacion inmunogenica para mejorar la utilizacion de elementos nutritivos por los animales rumiantes o similares a los rumiantes.
AU8126694A (en) 1993-10-26 1995-05-22 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
AU697144B2 (en) 1994-01-20 1998-10-01 Agresearch Limited Device for administration of beneficial materials to ruminants
NZ278977A (en) 1994-01-20 1997-03-24 Pastoral Agric Res Inst Nz Ltd Sustained release bolus for ruminants
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
AUPN353695A0 (en) 1995-06-14 1995-07-06 Commonwealth Scientific And Industrial Research Organisation Immunogenic preparation and method for improving the productivity of ruminant animals
US6503729B1 (en) * 1996-08-22 2003-01-07 The Board Of Trustees Of The University Of Illinois Selected polynucleotide and polypeptide sequences of the methanogenic archaeon, methanococcus jannashii
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002326949A1 (en) 2001-09-18 2003-05-12 The Board Of Regents Of The University Of Nebraska Method for the inhibition of methanogenesis
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003076575A2 (en) * 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
SE523209C2 (sv) * 2002-05-14 2004-04-06 Akzo Nobel Nv Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
MX340736B (es) * 2007-09-25 2016-07-22 Pastoral Greenhouse Gas Res Ltd * Vacunas y componentes de vacunas para inhibicion de celulas microbianas.
CN101434924A (zh) * 2008-12-17 2009-05-20 中南大学 一种分离严格厌氧产甲烷古菌的方法
AR077992A1 (es) * 2009-08-27 2011-10-05 Pastoral Greenhouse Gas Res Ltd Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium
CN101864362B (zh) * 2010-05-19 2012-05-09 江苏加德绿色能源有限公司 一种复合微生物菌剂及其应用
DE102011119230B4 (de) * 2011-11-23 2013-07-11 Audi Ag Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte
JP2016511630A (ja) * 2012-12-21 2016-04-21 ダニスコ・ユーエス・インク 代案の下流メバロン酸経路を使用するイソプレン、イソプレノイド、およびイソプレノイド前駆体の生成

Also Published As

Publication number Publication date
AR068552A1 (es) 2009-11-18
WO2009041830A2 (en) 2009-04-02
WO2009041832A9 (en) 2009-10-22
RU2010116163A (ru) 2011-11-10
CL2008002860A1 (es) 2009-06-05
AU2008304018A1 (en) 2009-04-02
JP6067209B2 (ja) 2017-01-25
US20100209998A1 (en) 2010-08-19
US20140220636A1 (en) 2014-08-07
WO2009041831A1 (en) 2009-04-02
ZA201001933B (en) 2013-10-30
JP5558356B2 (ja) 2014-07-23
DK3327030T3 (da) 2021-10-04
EP2203466A4 (en) 2011-04-13
AU2008304019A1 (en) 2009-04-02
CA2700162C (en) 2018-08-14
US8586709B2 (en) 2013-11-19
BR122021010737B1 (pt) 2021-09-21
EP2203470A4 (en) 2011-04-13
UY31360A1 (es) 2009-04-30
DK2203467T3 (en) 2017-03-27
AU2014210649A1 (en) 2014-09-04
EP2203467A4 (en) 2011-04-13
RU2528854C2 (ru) 2014-09-20
BR122020023381B1 (pt) 2021-09-08
CL2008002861A1 (es) 2009-03-06
ES2895908T3 (es) 2022-02-23
MX2010003328A (es) 2010-08-16
EP2203470A2 (en) 2010-07-07
BRPI0817299A2 (pt) 2015-06-16
AU2014210649B2 (en) 2016-09-08
CN101918431A (zh) 2010-12-15
JP5552053B2 (ja) 2014-07-16
US8592556B2 (en) 2013-11-26
US11926647B2 (en) 2024-03-12
WO2009041832A2 (en) 2009-04-02
JP2017046704A (ja) 2017-03-09
US20100209999A1 (en) 2010-08-19
JP2010539926A (ja) 2010-12-24
JP2015042166A (ja) 2015-03-05
CN101932595A (zh) 2010-12-29
US10590170B2 (en) 2020-03-17
CN101932595B (zh) 2016-02-10
WO2009041830A3 (en) 2009-07-02
EP2203467A1 (en) 2010-07-07
BRPI0817299A8 (pt) 2019-01-29
CN101918431B (zh) 2014-10-08
US20100221185A1 (en) 2010-09-02
CA2700164C (en) 2018-05-29
ES2587595T3 (es) 2016-10-25
ES2625144T3 (es) 2017-07-18
CA2700129A1 (en) 2009-04-02
MX2010003321A (es) 2010-08-03
EP2203466A2 (en) 2010-07-07
UY31359A1 (es) 2009-04-30
CL2008002859A1 (es) 2009-03-06
CN102015755A (zh) 2011-04-13
BRPI0817312B1 (pt) 2018-05-29
DK2203466T3 (en) 2016-07-25
BR122021010729B1 (pt) 2022-02-15
MX2010003319A (es) 2010-09-10
EP2203466B1 (en) 2016-04-06
WO2009041830A9 (en) 2009-08-27
US10995120B2 (en) 2021-05-04
CN107129524B (zh) 2023-11-21
US9296789B2 (en) 2016-03-29
CA2700129C (en) 2021-07-20
UY31361A1 (es) 2009-04-30
AR068551A1 (es) 2009-11-18
BRPI0817312A2 (pt) 2015-03-17
AU2008305846A1 (en) 2009-04-02
CA2700164A1 (en) 2009-04-02
CA2700162A1 (en) 2009-04-02
EP2203467B1 (en) 2016-12-14
JP2010539927A (ja) 2010-12-24
CN107129524A (zh) 2017-09-05
NZ745324A (en) 2023-02-24
US20170342112A1 (en) 2017-11-30
WO2009041832A3 (en) 2009-06-11
US20200325180A1 (en) 2020-10-15
EP3936516A1 (en) 2022-01-12
MX340736B (es) 2016-07-22
JP2010539928A (ja) 2010-12-24
EP3327030B1 (en) 2021-07-21
EP3327030A1 (en) 2018-05-30
US20210332087A1 (en) 2021-10-28
WO2009041831A9 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
AR068553A1 (es) Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
CR20190319A (es) ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117)
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
CL2011002660A1 (es) Anticuerpo anti-receptor de activinas tipo iib (anti-actr-iib); secuencia de polinucleotidos aislados que codifica dicho anticuerpo; vector, celula huesped; composicion farmaceutica; uso para tratar transtornos musculo esqueleticos.
CO6680688A2 (es) Anticuerpos para el receptor del factor de crecimiento epidérmico 3(her3)
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
CL2011002768A1 (es) Polipéptido mutante fgf21; ácido nucleico que lo codifica; vector; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar un trastorno metabólico.
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
PA8836801A1 (es) Polipeptidos g-csf de bovino modificados y sus usos
CO6670523A2 (es) Anticuerpos específicos para proteína de activación fibroblástica (fap), polinucleotidos que codifican dichos anticuerpos, y vectores y células huesped que comprenden dichos nucleótidos
BR112015022491A2 (pt) variantes de inibidor de tecido de metaloprotease tipo três (timp-3), ácido nucleico isolado, vetor de expressão, célula hospedeira isolada e método para produzir uma muteína de timp-3 recombinante, bem como composição e seu uso
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
CL2012000752A1 (es) Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios.
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
UY32866A (es) Secuencia genómica completa del metanógeno methanobrevibacter ruminantium
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso

Legal Events

Date Code Title Description
FG Grant, registration